CN1750844A - 用于预防和治疗与局部缺血-再灌注损伤相关的组织损伤的方法 - Google Patents
用于预防和治疗与局部缺血-再灌注损伤相关的组织损伤的方法 Download PDFInfo
- Publication number
- CN1750844A CN1750844A CNA2004800045401A CN200480004540A CN1750844A CN 1750844 A CN1750844 A CN 1750844A CN A2004800045401 A CNA2004800045401 A CN A2004800045401A CN 200480004540 A CN200480004540 A CN 200480004540A CN 1750844 A CN1750844 A CN 1750844A
- Authority
- CN
- China
- Prior art keywords
- antibody
- function equivalent
- equivalent fragment
- complement
- mbl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 85
- 206010063837 Reperfusion injury Diseases 0.000 title claims abstract description 34
- 208000012947 ischemia reperfusion injury Diseases 0.000 title claims abstract description 32
- 230000000451 tissue damage Effects 0.000 title abstract description 7
- 231100000827 tissue damage Toxicity 0.000 title abstract description 7
- 239000004074 complement inhibitor Substances 0.000 claims abstract description 61
- 229940124073 Complement inhibitor Drugs 0.000 claims abstract description 45
- 230000037361 pathway Effects 0.000 claims abstract description 38
- 201000008982 Thoracic Aortic Aneurysm Diseases 0.000 claims abstract description 17
- 208000007474 aortic aneurysm Diseases 0.000 claims abstract description 17
- 102000004856 Lectins Human genes 0.000 claims abstract description 12
- 108090001090 Lectins Proteins 0.000 claims abstract description 12
- 239000002523 lectin Substances 0.000 claims abstract description 12
- 101001056015 Homo sapiens Mannan-binding lectin serine protease 2 Proteins 0.000 claims abstract description 7
- 102100026046 Mannan-binding lectin serine protease 2 Human genes 0.000 claims abstract description 7
- 101150104297 MASP1 gene Proteins 0.000 claims abstract description 6
- 101001055956 Homo sapiens Mannan-binding lectin serine protease 1 Proteins 0.000 claims abstract description 5
- 102100026061 Mannan-binding lectin serine protease 1 Human genes 0.000 claims abstract description 5
- 239000012634 fragment Substances 0.000 claims description 86
- 108010087870 Mannose-Binding Lectin Proteins 0.000 claims description 44
- 102000009112 Mannose-Binding Lectin Human genes 0.000 claims description 44
- 208000037816 tissue injury Diseases 0.000 claims description 41
- 230000024203 complement activation Effects 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 29
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 28
- 230000000295 complement effect Effects 0.000 claims description 25
- 238000011282 treatment Methods 0.000 claims description 18
- 102000005962 receptors Human genes 0.000 claims description 14
- 108020003175 receptors Proteins 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 239000000910 agglutinin Substances 0.000 claims description 8
- 101710186708 Agglutinin Proteins 0.000 claims description 7
- 101710146024 Horcolin Proteins 0.000 claims description 7
- 101710189395 Lectin Proteins 0.000 claims description 7
- 101710179758 Mannose-specific lectin Proteins 0.000 claims description 7
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 claims description 7
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 7
- 108010009575 CD55 Antigens Proteins 0.000 claims description 6
- 102100022002 CD59 glycoprotein Human genes 0.000 claims description 6
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 claims description 6
- 230000004927 fusion Effects 0.000 claims description 6
- 102000050019 Membrane Cofactor Human genes 0.000 claims description 5
- 101710146216 Membrane cofactor protein Proteins 0.000 claims description 5
- 230000003449 preventive effect Effects 0.000 claims description 5
- 238000011287 therapeutic dose Methods 0.000 claims description 5
- 108700040183 Complement C1 Inhibitor Proteins 0.000 claims description 4
- 102000055157 Complement C1 Inhibitor Human genes 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 102100037084 C4b-binding protein alpha chain Human genes 0.000 claims description 3
- 101710159767 C4b-binding protein alpha chain Proteins 0.000 claims description 3
- 102100030386 Granzyme A Human genes 0.000 claims description 3
- 101001009599 Homo sapiens Granzyme A Proteins 0.000 claims description 3
- 102000011782 Keratins Human genes 0.000 claims description 3
- 108010076876 Keratins Proteins 0.000 claims description 3
- 108010085169 Lysine carboxypeptidase Proteins 0.000 claims description 3
- 108010031318 Vitronectin Proteins 0.000 claims description 3
- 102100035140 Vitronectin Human genes 0.000 claims description 3
- 239000000893 inhibin Substances 0.000 claims description 3
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000002464 receptor antagonist Substances 0.000 claims description 3
- 229940044551 receptor antagonist Drugs 0.000 claims description 3
- RDTRHBCZFDCUPW-KWICJJCGSA-N 2-[(4r,7s,10s,13s,19s,22s,25s,28s,31s,34r)-4-[[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-34-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-7-[3-(diaminomethylideneamino)propyl]-10,13-bis(1h-imidazol-5-ylmethyl)-19-(1h-indol Chemical compound C([C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CSSC[C@@H](C(N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)NCC(=O)N[C@@H](CC=2NC=NC=2)C(=O)N1)C(C)C)C(C)C)=O)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)C1=CN=CN1 RDTRHBCZFDCUPW-KWICJJCGSA-N 0.000 claims description 2
- 108010027437 compstatin Proteins 0.000 claims description 2
- 230000008439 repair process Effects 0.000 abstract description 23
- 230000015572 biosynthetic process Effects 0.000 abstract description 10
- 102000000989 Complement System Proteins Human genes 0.000 abstract description 5
- 108010069112 Complement System Proteins Proteins 0.000 abstract description 5
- 102100026553 Mannose-binding protein C Human genes 0.000 abstract 1
- 101710110798 Mannose-binding protein C Proteins 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 46
- 241000282414 Homo sapiens Species 0.000 description 38
- 108060003951 Immunoglobulin Proteins 0.000 description 22
- 102000018358 immunoglobulin Human genes 0.000 description 22
- 210000002381 plasma Anatomy 0.000 description 19
- 210000000440 neutrophil Anatomy 0.000 description 17
- 229920001184 polypeptide Polymers 0.000 description 16
- 102000004196 processed proteins & peptides Human genes 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 238000005516 engineering process Methods 0.000 description 15
- 108010067641 Complement C3-C5 Convertases Proteins 0.000 description 14
- 102000016574 Complement C3-C5 Convertases Human genes 0.000 description 14
- 102100022133 Complement C3 Human genes 0.000 description 13
- 101000901154 Homo sapiens Complement C3 Proteins 0.000 description 13
- 230000004913 activation Effects 0.000 description 13
- 239000000427 antigen Substances 0.000 description 13
- 210000004408 hybridoma Anatomy 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 230000002950 deficient Effects 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 102100031506 Complement C5 Human genes 0.000 description 10
- 101000941598 Homo sapiens Complement C5 Proteins 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 9
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 9
- 108090001005 Interleukin-6 Proteins 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 230000002163 immunogen Effects 0.000 description 9
- 102000003390 tumor necrosis factor Human genes 0.000 description 9
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 8
- 108090001007 Interleukin-8 Proteins 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 208000028867 ischemia Diseases 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 102000003777 Interleukin-1 beta Human genes 0.000 description 7
- 108090000193 Interleukin-1 beta Proteins 0.000 description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 description 7
- 230000003187 abdominal effect Effects 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 201000000050 myeloid neoplasm Diseases 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 108010063045 Lactoferrin Proteins 0.000 description 6
- 102000010445 Lactoferrin Human genes 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 208000035965 Postoperative Complications Diseases 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010058046 Post procedural complication Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 210000000709 aorta Anatomy 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000005482 chemotactic factor Substances 0.000 description 5
- 230000004154 complement system Effects 0.000 description 5
- 239000002131 composite material Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 210000003141 lower extremity Anatomy 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 210000001835 viscera Anatomy 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 4
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 108010022999 Serine Proteases Proteins 0.000 description 4
- 102000012479 Serine Proteases Human genes 0.000 description 4
- 208000002223 abdominal aortic aneurysm Diseases 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- -1 thienyl amidine Chemical class 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 3
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000003896 Myeloperoxidases Human genes 0.000 description 3
- 108090000235 Myeloperoxidases Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 206010033799 Paralysis Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 210000002376 aorta thoracic Anatomy 0.000 description 3
- 239000008135 aqueous vehicle Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 150000001720 carbohydrates Chemical group 0.000 description 3
- 238000005336 cracking Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 210000002254 renal artery Anatomy 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
- 108010003529 Alternative Pathway Complement C3 Convertase Proteins 0.000 description 2
- 206010002329 Aneurysm Diseases 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 206010003504 Aspiration Diseases 0.000 description 2
- 208000037157 Azotemia Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102400000626 C3-beta-c Human genes 0.000 description 2
- 101800000261 C3-beta-c Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108010034358 Classical Pathway Complement C3 Convertase Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 2
- 101001056128 Homo sapiens Mannose-binding protein C Proteins 0.000 description 2
- 102100025390 Integrin beta-2 Human genes 0.000 description 2
- 229920000057 Mannan Polymers 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 108010005642 Properdin Proteins 0.000 description 2
- 102100038567 Properdin Human genes 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 229940125644 antibody drug Drugs 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000000981 bystander Effects 0.000 description 2
- 229940009550 c1 esterase inhibitor Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 210000000080 chela (arthropods) Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003601 intercostal effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 229920000642 polymer Chemical group 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 229940126586 small molecule drug Drugs 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 208000009852 uremia Diseases 0.000 description 2
- 229960001722 verapamil Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- NXDSVCJDNFCUBP-UHFFFAOYSA-N 2-sulfanylbutanamide Chemical compound CCC(S)C(N)=O NXDSVCJDNFCUBP-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 108010083822 Alternative Pathway Complement C5 Convertase Proteins 0.000 description 1
- 102000005590 Anaphylatoxin C5a Receptor Human genes 0.000 description 1
- 108010059426 Anaphylatoxin C5a Receptor Proteins 0.000 description 1
- 206010065558 Aortic arteriosclerosis Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010013457 Dissociation Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010022680 Intestinal ischaemia Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- AXISYYRBXTVTFY-UHFFFAOYSA-N Isopropyl tetradecanoate Chemical class CCCCCCCCCCCCCC(=O)OC(C)C AXISYYRBXTVTFY-UHFFFAOYSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 102000004722 NADPH Oxidases Human genes 0.000 description 1
- 108010002998 NADPH Oxidases Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000036982 Spinal cord ischaemia Diseases 0.000 description 1
- 241000269319 Squalius cephalus Species 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 description 1
- 229920000392 Zymosan Polymers 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 238000005844 autocatalytic reaction Methods 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000011976 chest X-ray Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 102000006834 complement receptors Human genes 0.000 description 1
- 108010047295 complement receptors Proteins 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 208000018459 dissociative disease Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000013171 endarterectomy Methods 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 108090000062 ficolin Proteins 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 125000002541 furyl group Chemical class 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000003500 gene array Methods 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 150000004676 glycans Chemical group 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- OTQCKZUSUGYWBD-BRHMIFOHSA-N lepirudin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)[C@@H](C)O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 OTQCKZUSUGYWBD-BRHMIFOHSA-N 0.000 description 1
- 229960004408 lepirudin Drugs 0.000 description 1
- 201000002818 limb ischemia Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 210000003975 mesenteric artery Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 230000008383 multiple organ dysfunction Effects 0.000 description 1
- 239000010813 municipal solid waste Substances 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 1
- 229910001000 nickel titanium Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000001662 opsonic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 244000144985 peep Species 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 208000030613 peripheral artery disease Diseases 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- NHDHVHZZCFYRSB-UHFFFAOYSA-N pyriproxyfen Chemical compound C=1C=CC=NC=1OC(C)COC(C=C1)=CC=C1OC1=CC=CC=C1 NHDHVHZZCFYRSB-UHFFFAOYSA-N 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000003375 selectivity assay Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 125000005630 sialyl group Chemical group 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003238 somatosensory effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008337 systemic blood flow Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000000659 thermocoagulation Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 239000003064 xanthine oxidase inhibitor Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
TAAA | 血管内支架 | 腹部 | P-值 | |
年龄(岁)体重(kg)性别(n)男性女性高血压否是高胆固醇血症否是糖尿病否是冠状动脉疾病否是尿毒症否是肺部疾病否是脑血管疾病否是吸烟者否是外周血管疾病否是疼痛否是病因动脉粥样硬化患者炎症1NS=统计上差异不显著 | 69(65-73)73(65-81)118019145190811190118172514172145162 | 74(65-80)65(53-103)241551513351335113512442 | 57(45-85)70(50-87)322323004100414114145050 | NS1NSNSNSNSNSNSNSNSNSNSp=0.01NSNS |
TAAA | 血管内支架 | 腹部 | p-值 | |
皮肤-皮肤时间(min)内脏局部缺血(min)下肢局部缺血(min)总局部缺血(min)移植物大小(mm)移植物类型(n)两分支型直型动脉内膜切除术ICU停留时间(days)呼吸机使用时间(hrs)输入量(mL) | 164(140-190)37(30-44)54(44-63)55(46-65)23(21-24)10901(1-2)11(8-26)3800(3100-4500) | 100(61-231)73(40-116)73(40-116)31(29-38)0601(全部)3050(1097-5947) | 189(132-233)72(45-98)72(40-116)15(14-16)2120(0-3)7400(6250-8250) | NS1NSNS<0.0010.040.004 |
TAAA | 血管内支架 | 腹部 | p-值 | |
死亡率术后并发症否是收缩变力性否是重插管法重新手术血栓栓塞心肌梗塞尿毒症胃肠衰竭多器官衰竭创口感染其他并发症 | 1109118231252324 | 05151000011011 | 04150000000000 | NS1NSNSNSNSNSNSNSNSNSNSNS |
Claims (33)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44906903P | 2003-02-21 | 2003-02-21 | |
US60/449,069 | 2003-02-21 | ||
PCT/US2004/005136 WO2004075837A2 (en) | 2003-02-21 | 2004-02-20 | Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010221441.6A Division CN101897969B (zh) | 2003-02-21 | 2004-02-20 | 补体抑制剂在制备用于预防或抑制组织损伤的药物中的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1750844A true CN1750844A (zh) | 2006-03-22 |
CN1750844B CN1750844B (zh) | 2010-09-08 |
Family
ID=32927493
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010221441.6A Expired - Fee Related CN101897969B (zh) | 2003-02-21 | 2004-02-20 | 补体抑制剂在制备用于预防或抑制组织损伤的药物中的用途 |
CN2004800045401A Expired - Fee Related CN1750844B (zh) | 2003-02-21 | 2004-02-20 | 凝集素途径特异性补体抑制剂在制备用于预防或抑制组织损伤的药物中的用途 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010221441.6A Expired - Fee Related CN101897969B (zh) | 2003-02-21 | 2004-02-20 | 补体抑制剂在制备用于预防或抑制组织损伤的药物中的用途 |
Country Status (9)
Country | Link |
---|---|
US (2) | US20060140939A1 (zh) |
EP (2) | EP1601377A4 (zh) |
JP (1) | JP2006518749A (zh) |
CN (2) | CN101897969B (zh) |
AU (1) | AU2004216176B2 (zh) |
CA (1) | CA2515453C (zh) |
HK (2) | HK1084603A1 (zh) |
MX (1) | MXPA05008570A (zh) |
WO (1) | WO2004075837A2 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104010656A (zh) * | 2011-09-24 | 2014-08-27 | 德国杰特贝林生物制品有限公司 | 使用免疫球蛋白和c1-抑制剂的联合疗法 |
CN104717975A (zh) * | 2012-06-18 | 2015-06-17 | 奥默罗斯公司 | 用于治疗各种疾病和病症的抑制masp-1和/或masp-2和/或masp-3的组合物和方法 |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7083786B2 (en) | 1997-04-03 | 2006-08-01 | Jensenius Jens Chr | MASP-2, a complement-fixing enzyme, and uses for it |
US20070160645A1 (en) * | 2001-10-25 | 2007-07-12 | Jakob Vinten-Johansen | PostConditioning System And Method For The Reduction Of Ischemic-Reperfusion Injury In The Heart And Other Organs |
AU2002336650B2 (en) | 2001-10-25 | 2008-06-05 | Emory University | Catheter for modified perfusion |
US7827077B2 (en) | 2003-05-02 | 2010-11-02 | Visa U.S.A. Inc. | Method and apparatus for management of electronic receipts on portable devices |
SI2374819T1 (sl) | 2003-05-12 | 2017-09-29 | Helion Biotech Aps | Protitelesa proteina MASP-2 |
CA2524534C (en) * | 2003-05-15 | 2012-12-11 | Sek Chung Fung | Methods and compositions for the prevention and treatment of sepsis |
US20060002937A1 (en) * | 2004-06-10 | 2006-01-05 | University Of Leicester | Methods for treating conditions associated with MASP-2 dependent complement activation |
US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
AU2013201558B2 (en) * | 2004-06-10 | 2016-03-31 | Omeros Corporation | Methods for treating conditions associated with MASP-2-dependent complement activation |
GB0412966D0 (en) * | 2004-06-10 | 2004-07-14 | Univ Leicester | Genetically modified non-human mammals and cells |
US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
AU2011265532B2 (en) * | 2004-06-10 | 2014-04-24 | Omeros Corporation | Methods for treating conditions associated with MASP-2-dependent complement activation |
JP2008525468A (ja) * | 2004-12-22 | 2008-07-17 | エモリー・ユニバーシティ | ポストコンディショニング臓器保護作用を増強する治療補助薬 |
US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
KR20170002684A (ko) * | 2005-11-04 | 2017-01-06 | 제넨테크, 인크. | 안질환 치료를 위한 보체 경로 억제제의 용도 |
PT1965831E (pt) * | 2005-12-21 | 2011-10-19 | Pharming Intellectual Pty Bv | Uso de inibidor c1 para a prevenção da lesão isquémia-reperfusão |
US8524453B2 (en) | 2006-02-10 | 2013-09-03 | The Brigham And Woman's Hospital, Inc. | Lectin complement pathway assays and related compositions and methods |
US8703136B2 (en) | 2006-10-10 | 2014-04-22 | Regenesance B.V. | Complement inhibition for improved nerve regeneration |
WO2009085475A1 (en) * | 2007-12-21 | 2009-07-09 | Sevrain Lionel C | Method for detection and treatment of aneurysms |
HUP0900319A2 (en) * | 2009-05-25 | 2011-01-28 | Eotvos Lorand Tudomanyegyetem | New peptides, method of producing therof and use thereof |
CN106390117A (zh) | 2009-10-16 | 2017-02-15 | 奥默罗斯公司 | 通过抑制masp‑2依赖性补体活化治疗弥散性血管内凝血的方法 |
CN103068396B (zh) * | 2010-03-02 | 2016-07-06 | 诺沃姆德治疗公司 | 抑制c5和备解素相互作用的抗-备解素抗体在制备抑制交替途径活化的药剂中的用途 |
WO2011112575A1 (en) * | 2010-03-08 | 2011-09-15 | Wake Forest University Health Sciences | Keratin biomaterials for treatment of ischemia |
US9011852B2 (en) | 2010-04-30 | 2015-04-21 | Alexion Pharmaceuticals, Inc. | Anti-C5a antibodies |
US20130324482A1 (en) * | 2010-07-09 | 2013-12-05 | Apellis Pharmaceuticals, Inc. | Compstatin analogs for treatment of rhinosinusitis and nasal polyposis |
US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
EP2694108B1 (en) | 2011-04-08 | 2018-06-06 | University Of Leicester | Methods for treating conditions associated with masp-2 dependent complement activation |
CN102304158B (zh) * | 2011-05-20 | 2014-07-30 | 中国人民解放军第二军医大学 | 酰化黄酮苷化合物及其在制备补体抑制剂药物中的应用 |
AU2012279288B2 (en) | 2011-07-01 | 2017-07-20 | The Trustees Of The University Of Pennsylvania | Anti-properdin antibodies and uses thereof |
AU2012296477B2 (en) | 2011-08-17 | 2017-04-27 | Keratin Biosciences, Inc. | Methods for extracting keratin proteins |
WO2013025941A1 (en) | 2011-08-17 | 2013-02-21 | Keranetics Llc | Low protein percentage gelling compositions |
US10531655B2 (en) | 2011-12-02 | 2020-01-14 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
AU2012356170B2 (en) | 2011-12-21 | 2016-06-16 | Novartis Ag | Compositions and methods for antibodies targeting Factor P |
RU2018114903A (ru) * | 2012-04-06 | 2019-03-04 | Омерос Корпорейшн | Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения пароксизмальной ночной гемоглобинурии |
US9926366B2 (en) | 2012-10-04 | 2018-03-27 | Novelmed Therapeutics, Inc. | Methods of treating a hemolytic disorder comprising administering anti-properdin antibodies |
SI3660033T1 (sl) | 2012-11-15 | 2021-09-30 | Apellis Pharmaceuticals, Inc. | Analogi kompstatina z dolgotrajnim delovanjem in sorodni sestavki in postopki |
KR102403299B1 (ko) | 2013-03-08 | 2022-06-03 | 체에스엘 베링 게엠베하 | 원격 허혈-재관류 손상의 치료 및 예방 |
US9827245B2 (en) | 2013-03-15 | 2017-11-28 | KeraNetics, LLC | Keratin compositions comprising halofuginone |
WO2014152391A1 (en) | 2013-03-15 | 2014-09-25 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
CN107318267B (zh) | 2013-08-12 | 2021-08-17 | 豪夫迈·罗氏有限公司 | 用于治疗补体相关的病症的组合物和方法 |
CN103788157B (zh) * | 2014-02-14 | 2016-04-06 | 天津科技大学 | 绒毛白蜡中一种香豆素衍生物及其制备工艺和应用 |
EA201692109A1 (ru) | 2014-05-01 | 2017-03-31 | Дженентек, Инк. | Варианты антител к фактору d и их применение |
RU2770099C2 (ru) | 2015-10-07 | 2022-04-14 | Апеллис Фармасьютикалс, Инк. | Схемы введения |
CN108289951A (zh) | 2015-10-30 | 2018-07-17 | 豪夫迈·罗氏有限公司 | 抗-因子d抗体和缀合物 |
EP3368090A1 (en) | 2015-10-30 | 2018-09-05 | H. Hoffnabb-La Roche Ag | Anti-factor d antibody variant conjugates and uses thereof |
JOP20170154B1 (ar) | 2016-08-01 | 2023-03-28 | Omeros Corp | تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة |
WO2018075474A1 (en) | 2016-10-17 | 2018-04-26 | Medical University Of South Carolina | Compositions and methods for treating central nervous system injury |
US11040107B2 (en) | 2017-04-07 | 2021-06-22 | Apellis Pharmaceuticals, Inc. | Dosing regimens and related compositions and methods |
GB201800620D0 (en) | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
KR20210024003A (ko) * | 2018-06-22 | 2021-03-04 | 오메로스 코포레이션 | 다양한 혈전성 질환 및 장애의 치료를 위한 masp-2 억제 조성물 및 방법 |
WO2020115095A2 (en) * | 2018-12-05 | 2020-06-11 | Glycardial Diagnostics, S.L. | Methods and compositions for the prevention and/or treatment of ischemia and of ischemia/reperfusion injury |
GB2583560A (en) | 2018-12-11 | 2020-11-04 | Admirx Inc | Fusion protein constructs for complement associated disease |
JP2022532069A (ja) | 2019-05-07 | 2022-07-13 | バイエル・アクチエンゲゼルシヤフト | Masp阻害化合物およびその使用 |
EP4011904A1 (en) | 2020-12-14 | 2022-06-15 | Bayer Aktiengesellschaft | Masp inhibitory compounds and uses thereof |
CA3200103A1 (en) | 2020-11-04 | 2022-05-12 | Bayer Aktiengesellschaft | Masp inhibitory compounds and uses thereof |
TW202305010A (zh) * | 2021-04-25 | 2023-02-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗masp2抗體、其抗原結合片段及醫藥用途 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6458360B1 (en) * | 1990-04-25 | 2002-10-01 | The Johns Hopkins University | Soluble complement regulatory molecules |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6086868A (en) * | 1997-04-30 | 2000-07-11 | Schering Corporation | Method for treating or preventing ischemia-reperfusion injury |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
EP1140171A4 (en) * | 1998-12-15 | 2002-03-13 | Brigham & Womens Hospital | METHODS AND PRODUCTS FOR REGULATING THE COMPLEMENT ACTIVATION ASSOCIATED WITH THE LECTIN COMPLEMENT SYSTEM |
US7273925B1 (en) * | 1998-12-15 | 2007-09-25 | Brigham And Women's Hospital, Inc. | Methods and products for regulating lectin complement pathway associated complement activation |
CA2360233A1 (en) | 1999-02-09 | 2000-08-17 | 3-Dimensional Pharmaceuticals, Inc. | Methods of treating c1s-mediated diseases and conditions, and compounds and compositions therefor |
AU781805B2 (en) * | 1999-08-13 | 2005-06-16 | Brigham And Women's Hospital | Inhibitors of the lectin complement pathway (LCP) and their use |
EP1238066A2 (en) * | 1999-12-02 | 2002-09-11 | Jens Christian Jensenius | Masp-3, a complement-fixing enzyme, and uses for it |
US7112414B2 (en) * | 2000-07-13 | 2006-09-26 | Jens Christian Jensenius | Masp-2, a complement-fixing enzyme, and uses for it |
IL156618A0 (en) | 2000-12-28 | 2004-01-04 | Altus Biologics Inc | Crystals of whole antibodies and fragments thereof, methods for the preparation thereof and diagnostic kits utilizing the same |
US7361339B2 (en) * | 2003-01-09 | 2008-04-22 | Alexion Pharmaceuticals, Inc. | Methods for reducing morality associated with acute myocardial infarction |
-
2004
- 2004-02-20 CN CN201010221441.6A patent/CN101897969B/zh not_active Expired - Fee Related
- 2004-02-20 CN CN2004800045401A patent/CN1750844B/zh not_active Expired - Fee Related
- 2004-02-20 WO PCT/US2004/005136 patent/WO2004075837A2/en active Search and Examination
- 2004-02-20 AU AU2004216176A patent/AU2004216176B2/en not_active Ceased
- 2004-02-20 US US10/545,700 patent/US20060140939A1/en not_active Abandoned
- 2004-02-20 EP EP04713419A patent/EP1601377A4/en not_active Withdrawn
- 2004-02-20 EP EP11183631A patent/EP2422812A1/en not_active Withdrawn
- 2004-02-20 JP JP2006503762A patent/JP2006518749A/ja active Pending
- 2004-02-20 MX MXPA05008570A patent/MXPA05008570A/es active IP Right Grant
- 2004-02-20 CA CA2515453A patent/CA2515453C/en not_active Expired - Fee Related
-
2006
- 2006-06-20 HK HK06106987.6A patent/HK1084603A1/xx not_active IP Right Cessation
-
2008
- 2008-06-13 US US12/139,192 patent/US20090017031A1/en not_active Abandoned
-
2011
- 2011-05-16 HK HK11104750.9A patent/HK1150751A1/zh not_active IP Right Cessation
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104010656A (zh) * | 2011-09-24 | 2014-08-27 | 德国杰特贝林生物制品有限公司 | 使用免疫球蛋白和c1-抑制剂的联合疗法 |
CN104010656B (zh) * | 2011-09-24 | 2016-02-24 | 德国杰特贝林生物制品有限公司 | 使用免疫球蛋白和c1-抑制剂的联合疗法 |
CN104717975A (zh) * | 2012-06-18 | 2015-06-17 | 奥默罗斯公司 | 用于治疗各种疾病和病症的抑制masp-1和/或masp-2和/或masp-3的组合物和方法 |
CN109908352A (zh) * | 2012-06-18 | 2019-06-21 | 奥默罗斯公司 | 抑制masp-1和/或masp-2和/或masp-3的组合物和方法 |
CN115040653A (zh) * | 2012-06-18 | 2022-09-13 | 奥默罗斯公司 | 抑制masp-1和/或masp-2和/或masp-3的组合物和方法 |
Also Published As
Publication number | Publication date |
---|---|
AU2004216176B2 (en) | 2008-04-03 |
US20090017031A1 (en) | 2009-01-15 |
CA2515453C (en) | 2013-09-24 |
MXPA05008570A (es) | 2005-11-04 |
AU2004216176A1 (en) | 2004-09-10 |
JP2006518749A (ja) | 2006-08-17 |
HK1150751A1 (zh) | 2012-01-13 |
WO2004075837A3 (en) | 2005-06-02 |
EP1601377A2 (en) | 2005-12-07 |
CN101897969B (zh) | 2014-04-02 |
CN1750844B (zh) | 2010-09-08 |
CN101897969A (zh) | 2010-12-01 |
CA2515453A1 (en) | 2004-09-10 |
WO2004075837A2 (en) | 2004-09-10 |
EP2422812A1 (en) | 2012-02-29 |
EP1601377A4 (en) | 2009-07-15 |
US20060140939A1 (en) | 2006-06-29 |
HK1084603A1 (en) | 2006-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1750844B (zh) | 凝集素途径特异性补体抑制剂在制备用于预防或抑制组织损伤的药物中的用途 | |
CN1787741B (zh) | 用于预防和治疗败血症的方法与组合物 | |
ES2768648T3 (es) | Composiciones y métodos para aumentar la semivida en suero de un agente terapéutico dirigido a C5 del complemento | |
CN100595210C (zh) | 淀粉样β(1-42)蛋白寡聚体、其衍生物及抗体、其制备方法和用途 | |
ES2314040T3 (es) | Anticuerpo anti-osteopontina y su uso. | |
BR112019013463A2 (pt) | Método para a modulação da atividade de inflamassoma e da inflamação nos pulmões | |
ZA200500068B (en) | Treatment of tnf related disorders | |
JP3818322B2 (ja) | コラーゲン分解促進剤 | |
HU220995B1 (hu) | TNF-antagonisták alkalmazása megnövekedett interleukin-6 szérumszinttel járó szepszis kezelésére szolgáló gyógyszerkészítmény előállítására | |
CN102580086A (zh) | 使用抗IL-1α抗体治疗癌症 | |
ES2365463T3 (es) | Fotoféresis extracorpórea en combinación con tratamiento anti-tnf. | |
CN104379165B (zh) | 炎症疾病治疗剂 | |
AU2005299802A1 (en) | Duffy antigen receptor for chemokines and use thereof | |
BR112020025504A2 (pt) | Anticorpo que induz a imunotolerância, linfócito induzido, e agente de terapia celular método terapêutico usando o linfócito induzido | |
JP2002516339A (ja) | LAIT/sCD14−蛋白質による抗生物質蛋白質およびペプチドの誘導 | |
Gradziuk et al. | BLOOD PRODUCTS IN THE MODERN PHARMACY | |
RU2272810C2 (ru) | Средство для активации стволовых клеток | |
KR100414505B1 (ko) | 높은혈청수준의인터류킨-6을갖는질환을치료하기위한약물로서의항-tnf항체의용도 | |
RU2272650C2 (ru) | Способ получения антисыворотки против пептидов каудальной нейросекреторной системы (кнсс) млекопитающих | |
EP1752163A1 (en) | Agent for actively restoring structure and functions of damaged tissues and organs | |
JPH06509541A (ja) | 免疫複合体 | |
US20150224144A1 (en) | Anti-complement therapy compositions and methods for preserving stored blood | |
CN110312530A (zh) | 用以治疗心肌梗塞的可重复装载的水胶系统 | |
IL190101A (en) | Anti-sr – b1 antibodies and preparations containing them for the diagnosis and treatment of inflammation | |
WO2006080867A1 (fr) | Produit de stimulation de la secretion du facteur viii de coagulation sanguine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1084603 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: GENENTECH INC. Free format text: FORMER OWNER: TANOX INC. Effective date: 20090925 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20090925 Address after: Delaware Applicant after: Genentech Inc. Address before: texas Applicant before: Tanox Inc. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1084603 Country of ref document: HK |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100908 Termination date: 20160220 |
|
CF01 | Termination of patent right due to non-payment of annual fee |